Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 01, 2025 03:24 ET | Source: Pharma Equity Group A/S

Bestyrelsens beslutning om udstedelse af konvertible lån

Bestyrelsens beslutning om udstedelse af konvertible lån 1. oktober 2025Meddelelse nr. 11 Bestyrelsen i Pharma Equity Group har truffet beslutning om udstedelse af konvertible lån i henhold...
October 01, 2025 03:24 ET | Source: Pharma Equity Group A/S

The Board of Directors' resolution on the issuance of convertible loans

The Board of Directors' resolution on the issuance of convertible loans October 1, 2025Announcement no. 11 The Board of Directors of Pharma Equity Group has decided to issue convertible...
September 02, 2025 04:04 ET | Source: Pharma Equity Group A/S

Korrektion: Pharma Equity Groups datterselskab, Reponex Pharmaceuticals A/S, har fået myndighedsgodkendelse til at igangsætte afgørende klinisk studie med RNX-011 til livstruende peritonitis

Pharma Equity Groups datterselskab, Reponex Pharmaceuticals A/S, har fået myndighedsgodkendelse til at igangsætte afgørende klinisk studie med RNX-011 til livstruende peritonitis Denne...
September 02, 2025 04:04 ET | Source: Pharma Equity Group A/S

Correction: Pharma Equity Group's subsidiary, Reponex Pharmaceuticals A/S, receives regulatory approval to initiate pivotal clinical trial with RNX-011 for life-threatening peritonitis

Pharma Equity Group's subsidiary, Reponex Pharmaceuticals A/S, receives regulatory approval to initiate pivotal clinical trial with RNX-011 for life-threatening peritonitis This company...
September 01, 2025 07:06 ET | Source: Pharma Equity Group A/S

Pharma Equity Groups datterselskab, Reponex Pharmaceuticals A/S, har fået myndighedsgodkendelse til at igangsætte afgørende klinisk studie med RNX-011 til livstruende peritonitis

Pharma Equity Groups datterselskab, Reponex Pharmaceuticals A/S, har fået myndighedsgodkendelse til at igangsætte afgørende klinisk studie med RNX-011 til livstruende peritonitis København, 01....
September 01, 2025 07:06 ET | Source: Pharma Equity Group A/S

Pharma Equity Group's subsidiary, Reponex Pharmaceuticals A/S, receives regulatory approval to initiate pivotal clinical trial with RNX-011 for life-threatening peritonitis

Pharma Equity Group's subsidiary, Reponex Pharmaceuticals A/S, receives regulatory approval to initiate pivotal clinical trial with RNX-011 for life-threatening peritonitis Copenhagen,...
August 14, 2025 03:07 ET | Source: Pharma Equity Group A/S

Halvårsrapport for perioden 1. januar – 30. juni 2025

Halvårsrapport for perioden 1. januar – 30. juni 2025 14. august 2025Meddelelse nr. 9 Bestyrelsen og direktionen i Pharma Equity Group A/S ("PEG", "Selskabet" eller "Koncernen") har den...
August 14, 2025 03:07 ET | Source: Pharma Equity Group A/S

Consolidated Interim Report 1 January – 30 June 2025

Consolidated Interim Report 1 January – 30 June 2025Key points from the H1-2025 report (period 1 January - 30 June 2025) 14 August 2025Announcement no. 9 On 14 August 2025, the Board of Directors...
July 01, 2025 11:31 ET | Source: Pharma Equity Group A/S

Bestyrelsens beslutning om udstedelse af konvertible lån

Bestyrelsens beslutning om udstedelse af konvertible lån 1. juli 2025Meddelelse nr. 8 Bestyrelsen i Pharma Equity Group har truffet beslutning om udstedelse af konvertible lån i henhold til...
July 01, 2025 11:31 ET | Source: Pharma Equity Group A/S

The Board of Directors' resolution on the issuance of convertible loans

The Board of Directors' resolution on the issuance of convertible loans July 1, 2025Announcement no. 8 The Board of Directors of Pharma Equity Group has decided to issue convertible loans in...